A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether the companies conspired to fix drug prices. This decision allows the litigation to proceed against Mylan and Aurobindo, as well as 24 other pharmaceutical companies.<\/p>\n
The antitrust litigation alleges that the pharmaceutical companies engaged in a conspiracy to fix prices, which is a violation of federal and state antitrust laws. The coalition of states, which is leading the litigation, claims that the companies’ alleged conspiracy has resulted in higher drug prices for consumers.<\/p>\n
The judge’s decision is a significant setback for Mylan and Aurobindo, which had sought to have the litigation dismissed. The companies had argued that the states lacked sufficient evidence to support their claims, but the judge disagreed. The decision means that the litigation will continue, and the companies will be required to defend themselves against the allegations.<\/p>\n
The litigation is part of a larger effort by states and federal authorities to crack down on alleged anticompetitive practices in the pharmaceutical industry. The industry has faced numerous lawsuits and investigations in recent years, and several companies have already settled allegations of price-fixing and other anticompetitive behaviors.<\/p>\n
The judge’s decision is a victory for the coalition of states, which is seeking to hold the pharmaceutical companies accountable for their alleged actions. The litigation is likely to continue for several years, and the outcome is uncertain. However, the decision to allow the litigation to proceed is a significant step forward for the states and consumers who are seeking relief from high drug prices.<\/p>\n
The case is being closely watched by the pharmaceutical industry and legal experts, who are interested in the potential implications of the litigation. A victory for the states could result in significant changes to the way pharmaceutical companies operate, and could lead to lower drug prices for consumers.<\/p>\n","protected":false},"excerpt":{"rendered":"
A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether the companies conspired to fix drug prices. This decision allows the litigation to proceed […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21,2],"tags":[],"class_list":["post-89778","post","type-post","status-publish","format-standard","hentry","category-aurobindo-pharma","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89791,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/aurobindo-pharma-acquires-khandelwal-labs-non-cancer-portfolio-for-%e2%82%b9325-crore\/","url_meta":{"origin":89778,"position":0},"title":"Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for \u20b9325 Crore.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for \u20b9325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market. Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89749,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/aurobindo-pharma-pushes-back-deadline-to-purchase-26-stake-in-swarnaakshu-solar\/","url_meta":{"origin":89778,"position":1},"title":"Aurobindo Pharma Pushes Back Deadline to Purchase 26% Stake in Swarnaakshu Solar","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma's strategy to diversify its business and invest in renewable energy. The company had initially planned to complete the acquisition by a certain deadline, but it\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89658,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/13\/will-aurobindo-pharma-limiteds-new-product-launches-drive-revenue-growth-in-year-quarterly-earnings-analysis-profit-outlook-on-earlytimes-in\/","url_meta":{"origin":89778,"position":2},"title":"Will Aurobindo Pharma Limited’s New Product Launches Drive Revenue Growth in YEAR – Quarterly Earnings Analysis & Profit Outlook on earlytimes.in","author":"Team Small News","date":"December 13, 2025","format":false,"excerpt":"Aurobindo Pharma Limited, a leading pharmaceutical company, is expected to witness a significant boost in revenue due to the launch of new products. The company has been consistently expanding its product portfolio, and the latest launches are anticipated to contribute substantially to its top-line growth. In this article, we will\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89809,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/indian-pharma-q3-preview-strong-domestic-formulations-segment-to-offset-us-pricing-challenges-scanx-trade\/","url_meta":{"origin":89778,"position":3},"title":"Indian Pharma Q3 Preview: Strong Domestic Formulations Segment to Offset US Pricing Challenges – scanx.trade","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to experience a mixed bag in the third quarter of the year, with domestic formulations likely to counterbalance the pressure from pricing in the US market. The sector's growth is anticipated to be driven by a strong performance in the domestic market, which is\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89810,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/will-indian-pharmaceuticals-domestic-offerings-provide-a-buffer-against-pricing-pressures-from-the-us-market-in-the-third-quarter\/","url_meta":{"origin":89778,"position":4},"title":"Will Indian pharmaceuticals’ domestic offerings provide a buffer against pricing pressures from the US market in the third quarter?","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to have a mixed third quarter, with domestic formulations and specialty launches driving growth despite US pricing pressure. Companies like Sun Pharmaceuticals and Lupin are likely to lead the way, driven by their specialty businesses. Sun Pharma's revenue is expected to grow in the\u2026","rel":"","context":"In "Divi's Laboratories"","block_context":{"text":"Divi's Laboratories","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/divis-laboratories\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89762,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/the-high-court-has-asked-novo-nordisk-to-respond-to-natcos-request-to-cancel-its-patent\/","url_meta":{"origin":89778,"position":5},"title":"The High Court has asked Novo Nordisk to respond to Natco’s request to cancel its patent.","author":"Team Small News","date":"January 7, 2026","format":false,"excerpt":"The Delhi High Court has ordered Novo Nordisk, a Danish pharmaceutical company, to respond to a petition filed by Natco Pharma, a Hyderabad-based company, seeking to revoke the patent on the diabetes and anti-obesity drug semaglutide. The patent, which is set to expire in March, has been a subject of\u2026","rel":"","context":"In "Natco"","block_context":{"text":"Natco","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/natco\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89778"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89778\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}